Panelists discuss how emerging, better-tolerated oral therapies for idiopathic pulmonary fibrosis (IPF) and progressive ...

Panelists discuss recent trial data demonstrating that a novel agent not only slows lung function decline but also delays ...

While pulmonary fibrosis and emphysema are distinct conditions, they can co-occur. ... Pathophysiology refers to the effects on the body that a condition can cause.

VIENNA — Treatment with a novel lysophosphatidic acid receptor 1 (LPA1) antagonist was associated with significant changes in baseline biomarkers of disease in adults with pulmonary fibrosis ...

Chronic bronchial inflammation induced by CS promotes lung injury, fibrosis and remodeling, finally leading to emphysema, a lung condition that causes shortness of breath.

Please use one of the following formats to cite this article in your essay, paper or report: APA. Smith, Yolanda. (2023, March 11). Idiopathic Pulmonary Fibrosis Triggers.

New Chinese Medical Journal Pulmonary and Critical Care Medicine study provides key insights into pathogenesis mechanisms of lung fibrosis Chinese Medical Journals Publishing House Co., Ltd. Journal ...

Chinese scientists have developed a novel nanotherapy known as biomimetic extracellular vesicle spherical nucleic acids ...

“Fibrosis is the final path of nearly every form of chronic disease, regardless of the pathogenesis,” wrote the researchers. “Upon chronic injury, activated, fibrogenic fibroblasts deposit ...

Post-COVID pulmonary fibrosis, which involves scarring of the lungs that can worsen over time and may require a lung transplant, affects some patients after infection, according to pulmonologists.

The University of Texas at Tyler was awarded a $219,000 grant to help fund a professor’s pulmonary fibrosis treatment project ...